江苏宏信超市连锁股份有限公司JIANGSU HORIZON CHAIN SUPERMARKET COMPANY LIMITED02625.HK
食用油占批发收入约62.8%至68.2%
For FY2021, FY2022, FY2023, 9M2023 and 9M2024, sales of oil accounted for (i) approximately 74.6%, 73.4%, 70.0%, 72.3% and 73.2% of our revenue from sales of food under our wholesales, respectively; and (ii) approximately 67.7%, 62.8%, 64.2%, 67.5% and 68.2% of our revenue from wholesales, respectively.
Summary · 第 2 页
As an illustration of the significance of our collaboration with Yihai Kerry to the growth of our wholesale operations, our revenue from sales of oil under our wholesales increased significantly from approximately RMB311.0 million for FY2022 to approximately RMB436.1 million for FY2023, and increased significantly from approximately RMB293.3 million for 9M2023 to approximately RMB387.6 million for 9M2024.
江苏宏信超市连锁股份有限公司JIANGSU HORIZON CHAIN SUPERMARKET COMPANY LIMITED02625.HK
收入集中江苏省，尤以扬州为主
During the Track Record Period, a significant amount of our revenue was generated from Jiangsu Province, particularly Yangzhou.
Financial Information · 第 395 页
As at the Latest Practicable Date, we operated 51 supermarkets and 109 convenience stores in Jiangsu Province, out of which 49 supermarkets and 108 convenience stores are located in Yangzhou, and two supermarkets and one convenience store are located in Taizhou.
江苏宏信超市连锁股份有限公司JIANGSU HORIZON CHAIN SUPERMARKET COMPANY LIMITED02625.HK
江都商城占商场一般销售收入逾95%
During the Track Record Period, our revenue from general sales in Malls was substantially contributed by Jiangdu Mall* (江都商城), which accounted for over 95% of our revenue from general sales in Malls.
Business · 第 241 页
Overall, the entire Jiangdu Mall contributed an aggregate of approximately 13.4%, 7.9%, 9.9%, and 9.9% to our total revenue for each of FY2021, FY2022, FY2023 and 9M2024, respectively.
Babycare products, including baby diapers, baby pants, and, to a lesser extent, baby wipes, are particularly significant, accounting for approximately 86.8%, 78.9%, 71.5%, 78.9% and 55.0% of our revenue during the Track Record Period.
Financial Information · 第 274 页
Among our revenue from Contract Manufacturing which was primarily generated in Eurasia, approximately 94.5%, 98.8%, 98.3%, and 87.8% were attributable to the sale of our babycare products
Summary · 第 3 页
During the Track Record Period, profitability varies among the three main product categories particularly, babycare and adult incontinence products generally offered lower gross profit margins compared to feminine care products. The product mix significantly affects overall profitability.
Our revenue derived from sales of gold was 78.5%, 84.6%, 87.6%, 88.3% and 89.4% in 2021, 2022 and 2023 and the nine months ended September 30, 2023 and 2024.
Financial Information · 第 471 页
As such, fluctuations in gold and non-ferrous metal prices directly affect our results of operations.
We have established provincewide networks with a critical mass in eight provinces, which collectively accounted for 87% of our GMV in 2023, and led us to become one of China’s largest freshly-made tea store brands.
Summary · 第 2 页
As of December 31, 2023, our store count in second-tier and below cities accounted for 79% of our total store count, the highest percentage as compared to those of the other top five mid-priced freshly-made tea store brands in China, and slightly increased to 80% as of September 30, 2024.
During the Track Record Period, a significant portion of our revenue was generated from the sale of our ICV simulation testing software and platforms and ICV data platforms and other products, which were generally entered into on a project-by-project basis and non-recurring in nature.
Summary · 第 3 页
For example, during FY2021, a majority (approximately 96.1%) of our total revenue for FY2021 was derived from the sale of products (including approximately 56.9% from the sale of ICV simulation testing software and platforms and approximately 39.2% from the sale of ICV data platforms and other products), and only approximately 2.1% and 1.8% of our total revenue was derived from the provision of ICV testing and related services, and advisory and other services, respectively.
Business · 第 311 页
A majority of our revenue during the Track Record Period were generated from selling or building ICV simulation software and platforms and ICV data platforms and other products, which were generally one-off projects.
宜宾市商业银行股份有限公司YIBIN CITY COMMERCIAL BANK CO., LTD02596.HK
业务与服务网络集中于宜宾及四川地区
Our primary operations and service networks are based in Yibin, situated within the Sichuan Province of southwestern China.
Summary · 第 1 页
As of the Latest Practicable Date, the branch network of our Bank consisted of 40 facilities (including 39 branches and sub-branches and one head office), covering Yibin and Neijiang.
Summary · 第 2 页
As a city commercial bank headquartered in Yibin, our financial conditions and results of operations are influenced by local economic and industrial development.
脑动极光医疗科技有限公司BrainAurora Medical Technology Limited06681.HK
院内系统收入为总收入主要来源
A substantial portion of our revenue during the Track Record Period was generated from provision of the System integral software solutions in hospitals, which accounted for 42.1%, 36.1%, 61.3%, 62.3% and 68.0% of our total revenue in 2021, 2022, 2023, and the six months ended June 30, 2023 and 2024, respectively.
Business · 第 351 页
Building on our early success with respect to cognitive centers, we became the first organizer of a project initiated by the NHC, according to Frost & Sullivan, under which we are tasked with helping to establish cognitive centers in over 2,100 public hospitals across China and promoting the development of cognitive impairment DTx market in China over the next five years.
纽曼思健康食品控股有限公司Numans Health Food Holdings Company Limited02530.HK
藻油DHA产品收入占比逾九成
For FY2021, FY2022, FY2023, 6M2023 and 6M2024, the sales of our algal oil DHA products accounted for approximately 91.9%, 92.7%, 94.7%, 93.5% and 96.2% of our total revenue, respectively.
Summary · 第 1 页
Subsequent to the Track Record Period, algal oil DHA products remained to be our most important product category in terms of sales for the five months ended 30 November 2024, which constituted approximately 96.2% of our total revenue for the same period.
During the Track Record Period, we derived a large portion of revenue from PHC Services, which amounted to RMB215.6 million in 2021, RMB298.1 million in 2022, RMB239.8 million in 2023, RMB87.0 million in the six months ended June 30, 2023 and RMB55.0 million in the six months ended June 30, 2024, accounting for 57.9%, 63.2%, 43.1%, 44.7% and 24.0% of our total revenue in 2021, 2022 and 2023 and the six months ended June 30, 2023 and 2024, respectively.
Business · 第 205 页
While these policies do not prohibit bulk purchases, they prompted the government entities to adopt a more stringent procurement process for high-value contracts and resulted in a deceleration in the procurement and contract finalization process since the end of 2022 to early 2024.
Business · 第 205 页
Following this additional sales strategy, the revenue recognized from the county, district and community-level customers increased by 42.6% from RMB67.2 million in 2022 to RMB95.8 million in 2023 despite the overall decrease in revenue from our PHC Services from 2022 to 2023.
revenue from six-axis cobots accounted for 14.9%, 43.5%. 46.8%, 47.9% and 53.0% of our total revenue in 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively, and revenue from four-axis cobots accounted for 68.8%, 41.9%, 34.7%, 36.8% and 30.5% of our total revenue in the same years/periods, respectively.
Throughout the Track Record Period, we primarily derived our revenue from product sales of MAOGEPING, which contributed 96.6%, 98.4%, 99.0%, 99.0% and 99.3% of our total revenue from product sales in 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.
Summary · 第 2 页
We primarily operate two beauty brands: our flagship brand MAOGEPING and Love Keeps. We offer a selective portfolio of color cosmetics and skincare products under each brand, speaking to different consumer demographics.
We acquired Guyoudao from Hangzhou Huadong Medicine Group Co., Ltd. (杭州華東醫藥集團有限公司) in 2010 recognizing its promising prospects, and it generated a significant portion of our revenue during the Track Record Period.
Summary · 第 1 页
Because of our professional sales and marketing team and our established sales and distribution network, Guyoudao experienced rapid increase in sales volume and became our major revenue driver during the Track Record Period.
Summary · 第 6 页
As a result, there were only four commercialized rhBMP-2 products in the Chinese market as of the Latest Practicable Date, with Guyoudao being the earliest and the one with the largest market share, which is 85.5% in 2023.
江苏国富氢能技术装备股份有限公司Jiangsu Guofu Hydrogen Energy Equipment Co., Ltd.02582.HK
车载高压供氢系统贡献大部分收入
For the years ended December 31, 2021, 2022 and 2023 and the five months ended May 31, 2023 and 2024, we generated a majority of our revenue from vehicle-mounted highpressure hydrogen supply systems and related products and equipment for hydrogen refueling stations and related products.
Summary · 第 8 页
For example, the gross profit margin of equipment for hydrogen liquefaction and the storage and transportation of liquid hydrogen was 26.6% in 2023, compared to the gross profit margins of 18.4% of vehicle-mounted high-pressure hydrogen supply systems and related products and 12.6% of equipment for hydrogen refueling stations and related products in the same year.
Financial Information · 第 413 页
Although we have realized large-scale commercialization of vehicle-mounted high-pressure hydrogen supply systems and equipment for hydrogen refueling stations, we are also expanding our presence horizontally from the refueling and use of hydrogen energy to the production, storage and transportation of hydrogen energy, where we have self-developed equipment for hydrogen liquefaction and the storage and transportation of liquid hydrogen and water electrolysis hydrogen production equipment and related products.
The Asia Pacific Region is our core market, and accounted for more than 90% of our total shipping volume in 2023.
Financial Information · 第 391 页
During the Track Record Period, our container shipping network mainly consisted of the Asia Pacific Region, the Transpacific market and the Asia – Europe market.
Summary · 第 5 页
The majority of our fleet consists of small sized vessels each with capacity of less than 2,000 TEU, which are able to access most ports in the Asia Pacific Region and are therefore more versatile in deployment than larger vessels.
During the Track Record Period, our revenue was derived from the sales of Utidelone Injection.
Summary · 第 16 页
Currently, we primarily sell and market Utidelone Injection in China, and for the years ended December 31, 2022, 2023 and the five months ended May 31, 2024, our revenue amounted to RMB32.8 million, RMB66.6 million and RMB28.6 million, respectively.
Business · 第 351 页
Our Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of our product portfolio.
Revenue generated from our automotive solutions contributed a vast majority of our total revenue, accounting for 87.9%, 88.5%, 94.8%, 92.9% and 97.7% of total revenue in 2021, 2022 and 2023 and for the six months ended June 30, 2023 and 2024, respectively.
Summary · 第 16 页
Revenue mix from different revenue sources affect our profitability.
Financial Information · 第 377 页
In addition, we provided non-automotive solutions to our customers during the Track Record Period, the gross profit margin of which was generally lower than that of our automotive solutions.
华润饮料(控股)有限公司China Resources Beverage (Holdings) Company Limited02460.HK
包装饮用水贡献约九成收入
our revenue from packaged drinking water products increased by 2.7% from RMB6,648.0 million in the six months ended June 30, 2023 to RMB6,828.7 million in the same period of 2024, mainly as a result of increased customer demand for our products, as we enhanced penetration of the sales network and expanded the sales regions for certain products, particularly medium- to large-sized bottled water products, with revenue contribution increased by RMB160.5 million from RMB2,107.4 million in the six months ended June 30, 2023 to RMB2,267.9 million in the same period of 2024.
Summary · 第 23 页
Our small-sized bottled water products have been the flagship products under our C’estbon brand.
Financial Information · 第 327 页
In 2021, 2022 and 2023 and the four months ended April 30, 2023 and 2024, revenue generated from sales of medium- to large-sized bottled water products was RMB3,469.2 million, RMB3,962.3 million, RMB4,242.9 million, RMB1,177.1 million and RMB1,258.8 million, respectively, accounting for approximately 32.1%, 33.3%, 34.1%, 32.5% and 33.8% of our revenue generated from packaged drinking water products during the same periods, respectively.